Several investment firms have updated their stock ratings and price targets on shares of Biomarin Pharm (NASDAQ: BMRN) in the last week:

  • Biomarin Pharm had its “outperform” rating reaffirmed by analysts at RBC Capital.
  • Biomarin Pharm had its price target raised by analysts at Brean Murray from $41.00 to $47.00. They now have a “buy” rating on the stock.
  • Biomarin Pharm had its price target raised by analysts at William Blair from $46.00 to $49.00. They now have an “outperform” rating on the stock.
  • Biomarin Pharm had its price target raised by analysts at Summer Street from $45.00 to $52.00. They now have a “buy” rating on the stock.
  • Biomarin Pharm had its price target raised by analysts at Jefferies Group from $44.00 to $46.00. They now have a “buy” rating on the stock. They wrote, “Our experts discussions indicate probability of successful GALNS Ph3 for Morquio A syndrome (MPS IV) at ~60%-85%. If successful, we forecast ~25-30% upside from current levels (& BMRN will likely continue to trade up on additional pipeline potential). BMRN expects GALNS BLA filing in 1Q13, with potentially regulatory approval by 4Q13. We forecast GALNS to turn BMRN to profitability, with peak annual sales potential of ~$500M.”

Biomarin Pharm traded down 0.54% on Wednesday, hitting $40.75. Biomarin Pharm has a 52-week low of $30.06 and a 52-week high of $44.18. The company’s market cap is $5.035 billion.

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions.